Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.
Jennifer Kelly Shepphird, PhD
Advertisement
Articles by Jennifer Kelly Shepphird, PhD
The FDA approved nivolumab for patients with advanced melanoma in December 2014, joining 6 other melanoma treatments approved in the past 3 years, including monoclonal antibodies pembrolizumab and ipilimumab.
A bundled payment model may signal the expansion of cost reforms in oncology treatment.
Advertisement
Latest Updated Articles
Flat Rate Payment Pilots May Provide Guidance Toward ReformPublished: December 31st 2014 | Updated:
Costs of Immunotherapies Continue DebatePublished: December 31st 2014 | Updated:
Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma CollaborationPublished: January 6th 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
